ArticleJournal of clinical medicine2022

Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain).

Ricardo Ruiz-Villaverde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.